Countries China

Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs

On December 20, NMPA has approved a clinical trial for JMKX003801 to treat serious infection caused by Gram-negative bacteria. Drug resistance of anti...

 December 27, 2023 | News

GenSci Launches Global Innovation Hub in Shanghai

Changchun GeneScience Pharmaceutical ("GenSci"), a subsidiary of Changchun High-Tech Industries (Group), held a groundbreaking ceremony for its new global ...

 December 26, 2023 | News

Oncoshot Collaborates with Zhejiang Ablaze for Data-Driven Drug Development in China

This collaboration brings together complementary strengths - Oncoshot's capabilities in data analysis and insights generation with Ablaze's recent expansio...

 December 26, 2023 | News

TransThera Completes First Patient Dosing in US for Global Phase 3 Trial of Tinengotinib in FGFRi Relapsed/Refractory Cholangiocarcinoma

This study is a Phase 3, randomized, controlled, global multicenter study to evaluate the efficacy and safety of oral tinengotinib versus physician's choic...

 December 22, 2023 | News

Everest Medicines' Partner Calliditas Announces Nefecon® as Sole FDA-Approved Treatment for Slowing IgA Nephropathy Kidney Decline

The FDA approval is for adults with primary IgAN who are at risk for disease progression, irrespective of proteinuria levels. Nefecon® is now a...

 December 21, 2023 | News

BioCity Doses First Patient in Phase Ib/II Trial of BC3402 Anti-TIM-3 mAb with IMFINZI for Advanced Hepatocellular Carcinoma

The study is being conducted at Zhongshan Hospital with Prof. Jia Fan as the principal investigator. Dr. Fan is a world-renowned liver cancer sur...

 December 21, 2023 | News

CellOrigin Treats First CAR-M Patient in China, Unveils Second-Gen CAR-M for Solid Tumors

   "A single center, single-arm, dose-escalation, exploratory clinical trial to examine the safety, tolerability, pharmacokinetics and prelimina...

 December 21, 2023 | News

InxMed Licenses Next-Gen ADCs with Escugen

The license agreement provides InxMed with right to use EZWi-Fit® platform on the several novel ADC candidate molecules. InxMed will hav...

 December 20, 2023 | News

NMPA Accepts Mabwell's 8MW0511 Injection New Drug Application

8MW0511, a Class 1 therapeutic biological product, is a new generation of long-acting G-CSF (modified cytokine with high activity) with independent intelle...

 December 20, 2023 | News

InnoCare's TYK2 Inhibitor ICP-332 Meets Phase II Endpoint in Atomic Dermatitis Study

ICP-332 in AD patients treated for 4 weeks demonstrated excellent efficacy and safety profile. ICP-332 achieved multiple efficacy endpoints including Eczem...

 December 18, 2023 | News

GeneQuantum and BioMap Collaborate on Next-Gen ADC Therapeutics

The partnership will combine GQ's proprietary enzymatic site-specific conjugation technology platforms (iLDC® and iGDC®), linker-payload platform, ...

 December 18, 2023 | News

Clover Initiates Phase Ⅰ Clinical Trial for RSV Vaccine Candidate

Clover Biopharmaceuticals, Ltd.  a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save li...

 December 13, 2023 | News

Zhongchao Inc. Partners with Public Health Foundation for Cancer Treatment Advancements

The Project offers free Doxorubicin Hydrochloride Liposome Injections to low-income patients with breast cancer, lymphoma, Kaposi's sarcoma, ovarian cancer...

 December 12, 2023 | News

CStone's Sugemalimab Granted NMPA Approval for Esophageal Cancer

  Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for use in combination with fluorouracil and platinum-based chemotherapy...

 December 11, 2023 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close